KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q4 2025 value amounting to -$3.4 million.

  • Alnylam Pharmaceuticals' Other Non Operating Income rose 9584.4% to -$3.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$74.7 million, marking a year-over-year increase of 5863.34%. This contributed to the annual value of $5.2 million for FY2025, which is 10288.11% up from last year.
  • According to the latest figures from Q4 2025, Alnylam Pharmaceuticals' Other Non Operating Income is -$3.4 million, which was up 9584.4% from -$74.1 million recorded in Q3 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Other Non Operating Income registered a high of $19.0 million during Q1 2021, and its lowest value of -$80.8 million during Q4 2024.
  • Over the past 5 years, Alnylam Pharmaceuticals' median Other Non Operating Income value was -$24.9 million (recorded in 2023), while the average stood at -$27.8 million.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first surged by 308232.32% in 2021, then plummeted by 69155.97% in 2023.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Other Non Operating Income stood at -$30.5 million in 2021, then skyrocketed by 91.57% to -$2.6 million in 2022, then tumbled by 691.56% to -$20.4 million in 2023, then plummeted by 297.26% to -$80.8 million in 2024, then skyrocketed by 95.84% to -$3.4 million in 2025.
  • Its Other Non Operating Income was -$3.4 million in Q4 2025, compared to -$74.1 million in Q3 2025 and -$6.4 million in Q2 2025.